Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for cancer. Unlike autologous approaches that use a patient’s own cells, its candidates are designed as “off-the-shelf” products manufactured from healthy donor cells. The pipeline targets hematologic malignancies and other oncology indications through partnered and proprietary programs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -59.7 | — |
| Q2 2025 | 0 | — | -50.9 | — |
| Q3 2025 | 0 | — | -41.4 | — |
| Q4 2025 | 0 | — | -38.8 | — |
| Q1 2026 | 0 | — | -42.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Tiptree Inc. (TIPT), Sprout Social, Inc. (SPT), AGNT, Inc (AGNT), Peoples Financial Services Corp. (PFIS), Shenandoah Telecommunications Company (SHEN), Assembly Biosciences, Inc. (ASMB)